Monday 11th January, 2021, Royal Marsden Hospital London
Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
Description: In this half-day course (repeated Morning and afternoon) I describe the logic behind many immunotherapy-based cancer treatments such as checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab), adoptive cell transfer (CAR T cell therapy, infiltrating T cells), and vaccine-based treatments (peptide and DNA vaccines, oncolytic viruses, dendritic cell vaccines).
To book, contact: firstname.lastname@example.org or call: 020 7808 2922
The relationship between cancer and the immune system
- How cancer cells thrive alongside white blood cells
- The immune-suppressing cancer environment
Introduction to checkpoint inhibitors
- Checkpoint proteins on T cells
- Antibodies that target CTLA-4
- Antibodies that target PD-1 and PD-L1
Checkpoint inhibitors – progress to date
- Lessons learned
- Patterns of response and mechanisms of resistance
- Progress in biomarker-driven patient selection
Introduction to adoptive cell transfer methods
- CAR T cell therapy for acute leukaemia and other cancers
- Infiltrating T cell therapy for malignant melanoma
Introduction to vaccine-based treatments
- Peptide- and DNA-based vaccines
- Oncolytic viruses including T-VEC
- Dendritic cell vaccines
- Where have we got to?
- Where are we going?